Clinical Trials
4 trialsNCT01411267 2022-04-04
AC220 for Children With Relapsed/Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT00462761 2020-05-11
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Daiichi Sankyo
Phase 1 Completed
NCT01565668 2019-12-27
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Daiichi Sankyo
Phase 2 Completed
NCT00989261 2019-12-11
ACE
Daiichi Sankyo
Phase 2 Completed